Wednesday, October 14, 2026
ExploreSearch
Finance Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· December 26, 2025

Bull of the Day: Credo Technology (CRDO)

View original at nasdaq.com
Bull of the Day: Credo Technology (CRDO) Credo Technology Group (CRDO) is a key supplier of high-performance serial connectivity solutions for the hyperscale datacenter, 5G carrier, enterprise networking, HPC (high-performance computing), and AI/ML markets…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Amazon may have contributed as much as 85% of Credo's Q3 topline revenue, though Credo did not officially disclose this

    80% confidence

  • CRDO is a buy in the $40s price range

    80% confidence

  • NVIDIA has been creating new industries for almost eight years, with Jensen & Co. developing use cases by the thousands per year once data enterprises and universities caught on to GPU-CUDA capabilities

    80% confidence

  • Jensen talks about 1,000-fold advances in science, engineering, and social challenges due to NVIDIA's simulation and synthetic data capabilities

    80% confidence

  • Credo aims to break bandwidth barriers in the data infrastructure market and provides secure, high-speed connectivity solutions that deliver improved power efficiency

    80% confidence

  • Credo had seven customers that contributed more than 5% of revenue, and going forward expects three to four customers will be greater than 10% of revenue in coming quarters and fiscal year as additional hyperscalers ramp to more significant volumes

    80% confidence

  • Many important trends are driving the data infrastructure market, such as cloud workloads, streaming video, 5G wireless deployment, IoT expansion, and growing adoption of AI, creating an explosion of data that has stressed existing infrastructure

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com
Bull of the Day: Credo Technology (CRDO) — Source | Via News | Finance Via News